Autopsy report · NCT00296062

Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer

“Trial did not move to Phase II portion due to poor tolerance of treatment”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 5 years 2 months before it stopped.
• 12 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Case Comprehensive Cancer Center

Sponsor type

University, hospital or other

Conditions

Colorectal Cancer; Unspecified Adult Solid Tumor, Protocol Specific

Interventions

bevacizumab; capecitabine; irinotecan hydrochloride; oxaliplatin

Participants

12

Sites

1

Countries

United States

Trials that died the same way

• Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma
  “Decision made to not move forward with Phase II portion of trial” (79% match in meaning)
• Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
  “This study was terminated early due to other competing trials, therefore did not go on to the Phase II portion of the study.” (75% match in meaning)
• A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate
  “The decision was made to prematurely discontinue this trial due to lack of efficacy.” (73% match in meaning)
• Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
  “Trial terminated due to focus of primary therapeutic areas.” (72% match in meaning)
• Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
  “Trial terminated because of lack of efficacy in the short term acute phase” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.